SP-D binds the heavily glycosylated SARS-CoV-2 S-protein (68); and SP-D levels, found to be elevated in severe SARS-CoV-2-related pneumonia, via leakage from the damaged lung into blood, may be used as biomarkers of clinical course, follow-up, determination of disease severity, and possibly future treatments for COVID-19 disease (72–76). This evidence concerns the gene SFTPD and susceptibility to pneumonia measurement.